MHE August 2022

More of these treatments have been approved, but supply chain issues and cost remain obstacles.

Drug manufacturers are rejecting the program’s blanket discounts involving contract pharmacies. A flurry of litigation has ensued.

Most of the respondents to the survey agreed that negotiations by pharmacy benefit managers (PBMs) lowers net drug prices. About half favored imposing transparency rules on PBMs.

Some are offering travel benefits.

The respondents were almost evenly split on whether it was a mistake for the FDA to approve Aduhelm, but a large majority agreed that CMS made the right decision to restrict Medicare coverage to those enrolled in clinical trials.

Women traveling out of state for a medication abortion may wind up using telehealth.

Opinion was split evenly on preexposure prophylaxis as a strategy for preventing HIV infections.

Two-thirds of the respondents to our 2022 annual Pharmacy Survey believe that biosimilars will have a significant effect on drugs prices over the next several years.

Private equity firms have pulled back some this year, but money has been pouring into the healthcare sector. Will the cash infusion make healthcare more efficient or drive up costs as investors seek returns?

Our survey shows some optimism about the course of the COVID-19 pandemic, but concern about Paxlovid rebound. Former President Donald Trump’s job performance on COVID-19 was rated low while the World Health Organization and Pfizer were rated high.

Opinion piece on the top 5 priorities for managed care by Managed Healthcare Executive Editorial Advisory Board Member, Don Hall, M.P.H.,principal of DeltaSigma, LLC.

Nonsteroidal topical agents and TYK2 inhibitors may join an already full armamentarium.